IGURATIMOD
Background and Date of Approval
Iguratimod received approval from the United States Food and Drug Administration (FDA) on 18 April 2012.
Uses
Iguratimod is primarily used to treat rheumatoid arthritis, an autoimmune disorder characterized by joint inflammation and pain. As a disease-modifying antirheumatic drug (DMARD), this medication helps reduce inflammation, alleviate symptoms, and potentially slow disease progression. While investigational, it is also being explored for other autoimmune conditions like ankylosing spondylitis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, and Behçet's disease, indicating its potential broader application in managing various inflammatory and immune-related disorders.
How is it administered?
Iguratimod is typically administered orally, which means it is taken by mouth. It is available in tablets or capsules that are ingested with water. Always follow your healthcare provider's instructions regarding the correct dosage, timing, and frequency of administration for this medication.
Side Effects
Iguratimod use may lead to various side effects. Commonly observed effects encompass gastrointestinal discomfort, rash, elevated liver enzymes, and upper respiratory tract infections. In some cases, hematologic changes like anemia or thrombocytopenia may occur. Serious effects involve potential liver and allergic reactions, necessitating prompt medical attention. Vigilance for adverse effects and regular medical monitoring are essential to ensure this medication's safe and effective use.
Warnings
Be cautious of medication interactions and increased susceptibility to infections while on Iguratimod. Gastrointestinal side effects, such as nausea and diarrhea, may arise. Serious allergic reactions, though rare, can occur. Elevations in liver enzymes could be observed. Hematologic effects, such as changes in blood cell counts, including anemia or decreased platelet count, are possible. Pregnant and breastfeeding individuals should avoid this medication due to potential risks to the developing fetus or infant. Mood changes or depression can occur. Individuals may experience respiratory symptoms.
Precautions
Regularly monitor liver function, including liver enzyme levels, and promptly report any symptoms of liver problems to your healthcare provider. Undergo regular blood tests to monitor blood cell counts and promptly report any signs of unusual bleeding, bruising, or infections. Manage gastrointestinal upset with proper hydration and dietary adjustments, and inform your doctor if symptoms persist. Consider bone health monitoring and supplementation with calcium and vitamin D to mitigate potential effects on bone health. Discuss any history of heart disease, cardiovascular issues, or eye conditions with your doctor, and monitor related symptoms.
Word of Advice
Serious allergic reactions warrant immediate attention, particularly if rash, swelling, or breathing difficulties develop. Patients who are pregnant or breastfeeding should not use Iguratimod. Caution is advised if you have lung, liver, cardiovascular, or eye conditions; discuss bone health, immunisations, and mental health status with your doctor. Reduce alcohol intake, exercise care when driving or operating machinery if drowsiness occurs, and minimise sun exposure to your skin. Inform your doctor of all pre-existing medical conditions, active infections, or planned surgical procedures. Seek prompt medical attention if you develop unusual symptoms including respiratory issues or mood changes. Adhere to dosing instructions, keep scheduled follow-up appointments, and consult your doctor for guidance tailored to your individual health profile.
References
Huihui Jiang et al; Molecular mechanisms and clinical application of Iguratimod: A review; Biomedicine & Pharmacotherapy; Published on Feb 2020; Accessed on 09/08/2023; https://pubmed.ncbi.nlm.nih.gov/31918275/ Novartis Pharmaceuticals UK Ltd, Electronic medicines compendium (emc), [Revised on 25th Jul 2022] [Accessed on 9th August 2023], https://www.medicines.org.uk/emc/product/6658/smpc#gref Sisi Xie et al; Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape; Frontiers in Pharmacology; Published on 26/02/2020; Accessed on; 09/08/2023 http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7054862/ Jie Li et al; Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology; Bone Research; Published on Sept 2019; Accessed on 09/08/2023; http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6804744/
Frequently Asked Questions
Can Iguratimod be used long-term?
Long-term use of Iguratimod may be necessary to manage chronic autoimmune conditions. Your healthcare provider will determine the appropriate duration of treatment based on your individual needs and response.
What should I do if I miss a dose of Iguratimod?
If you miss a dose, take it as soon as you remember. However, if it's close to the time for your next dose, skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for a missed one.
Can I stop taking Iguratimod if my symptoms improve?
No, following your doctor's instructions regarding medication use is important. Stopping Iguratimod abruptly could lead to a flare-up of symptoms. Always consult your healthcare provider before making any changes to your treatment plan.
Can I continue my regular physical activities and exercise routine while on Iguratimod?
In general, you can continue your physical activities while taking Iguratimod. However, if you experience joint pain or other symptoms, consult your doctor for guidance on adjusting your exercise routine.
Is it safe to receive vaccinations while on Iguratimod?
Consult your healthcare provider before receiving any vaccines while on Iguratimod, as the medication may affect your immune response to vaccinations.
Can Iguratimod affect my vision?
While vision changes are not a common side effect, inform your healthcare provider if you experience any visual disturbances or eye discomfort.